2 unknown, 1 completed, 1 recruiting. 2 Phase 2, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Recruiting 1 |
| Not applicable | 1 | Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Local radiotherapy: new trials by email Literature Review of Local radiotherapy trials Research Report on Local radiotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery Pembrolizumab injection, Capecitabine tablets, Local radiotherapy - Triple Negative Breast Neoplasms | Phase 2 | Recruiting | UNICANCER | 220 | 2025-03-11 | 2025-11-17 |
| Chemotherapy Combination With Local Radiotherapy and rhGM-CSF for Oligometastatic Stage IV NSCLC Patients rhGM-CSF, Pemetrexed, Local Radiotherapy - Carcinoma, Non-Small-Cell Lung | Not applicable | Unknown | Shandong Cancer Hospital and Institute | 45 | 2018-01-15 | 2018-04-05 |
| Perioperative FOLFIRI VS Adjuvant FOLFIRI in Resectable Advanced CRC Failed to Oxaliplatin Irinotecan, 5-fluorouracil, Local radiotherapy - Colorectal Neoplasms, Effects of Chemotherapy | Phase 3 | Unknown | Sixth Affiliated Hospital, Sun Yat-sen University | 360 | 2011-01-01 | 2019-06-05 |
| A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas PF-3512676, Local radiotherapy - Lymphoma, Non-Hodgkin, Lymphoma | Phase 2 | Completed | Ronald Levy | 30 | 2009-01-01 | 2017-03-14 |
Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Neoplasm Metastasis (1) · Neoplasm Recurrence, Local (1) · Triple Negative Breast Neoplasms (1)
Ronald Levy (1) · Shandong Cancer Hospital and Institute (1) · Sixth Affiliated Hospital, Sun Yat-sen University (1) · UNICANCER (1)
China (2) · France (1) · United States (1)
Ping Lan, MD (1) · Ronald Levy (1)
2023 (1)